Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC

BACKGROUND: No biomarker is available to predict prognosis of patients with advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed a prospective-retrospective biomarker study within the MITO2 trial on the treatment of AOC. Patients and methods: MITO2 is a randomised multice...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Perrone, Francesco, Baldassarre, Gustavo, Indraccolo, Stefano, Signoriello, Simona, Chiappetta, Gennaro, Esposito, Franca, Ferrandina, Gabriella, Franco, Renato, Mezzanzanica, Delia, Sonego, Maura, Zulato, Elisabetta, Zannoni, Gian F., Canzonieri, Vincenzo, Scambia, Giovanni, Sorio, Roberto, Savarese, Antonella, Breda, Enrico, Scollo, Paolo, Ferro, Antonella, Tamberi, Stefano, Febbraro, Antonio, Natale, Donato, Maio, Massimo Di, Califano, Daniela, Scognamiglio, Giosuè, Lorusso, Domenica, Canevari, Silvana, Losito, Simona, Gallo, Ciro, Pignata, Sandro
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341934/
https://ncbi.nlm.nih.gov/pubmed/27655643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12056
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы